[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f97VWwya6C6qw4wzoNB2jOixjuWAG4Nn0j3YGgZU0TOw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":8,"totalEnrollment":9,"activePrograms":10,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":33,"phaseBuckets":39,"rows":46},"University of Dundee",[4],113,false,4,57190,1,55,[13,16,19,21,24,26,28,31],{"name":14,"count":15},"Asthma",15,{"name":17,"count":18},"Heart Failure",6,{"name":20,"count":18},"Hepatitis C",{"name":22,"count":23},"Chronic Obstructive Pulmonary Disease",5,{"name":25,"count":8},"Type 1 Diabetes",{"name":27,"count":8},"Allergic Rhinitis",{"name":29,"count":30},"Diabetes",3,{"name":32,"count":30},"Left Ventricular Hypertrophy",[34],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT06435156","Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes","2027-10-31","Sotagliflozin",[40,41,42,43,44,45],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[47,69,139,196,232,271,306,338,360,397,430,458,486,504,529,547,565,588,606,635,653,678,696,714,736,754,781,799,821,845,863,881,905,923,941,959,977,1002,1020,1038,1064,1082,1106,1130,1148,1172,1199,1217,1235,1262,1280,1298,1316,1342,1360,1378,1396,1414,1439,1457,1481,1499,1522,1547,1572,1605,1631,1649,1667,1685,1709,1741,1759,1777,1795,1813,1831,1849,1867,1885,1903,1926,1951,1969,1993,2018,2042,2060,2083],{"intervention":38,"totalTrials":10,"cells":48},{"EARLY_PHASE1":49,"PHASE1":52,"PHASE2":54,"PHASE3":63,"PHASE4":65,"NA":67},{"trials":50,"activeCount":51},[],0,{"trials":53,"activeCount":51},[],{"trials":55,"activeCount":10,"soonestReadout":37},[56],{"nctId":35,"briefTitle":36,"status":57,"phases":58,"primaryCompletion":37,"completion":37,"start":59,"enrollment":60,"conditions":61,"interventions":62},"RECRUITING",[42],"2025-01-28",320,[25,17],[38],{"trials":64,"activeCount":51},[],{"trials":66,"activeCount":51},[],{"trials":68,"activeCount":51},[],{"intervention":70,"totalTrials":23,"cells":71},"Allopurinol",{"EARLY_PHASE1":72,"PHASE1":74,"PHASE2":76,"PHASE3":78,"PHASE4":80,"NA":137},{"trials":73,"activeCount":51},[],{"trials":75,"activeCount":51},[],{"trials":77,"activeCount":51},[],{"trials":79,"activeCount":51},[],{"trials":81,"activeCount":51},[82,95,105,115,126],{"nctId":83,"briefTitle":84,"status":85,"phases":86,"primaryCompletion":87,"completion":88,"start":89,"enrollment":90,"conditions":91,"interventions":93},"NCT01550107","Allopurinol in Functional Impairment (ALFIE) Trial: 'Improving Muscle Strength'","COMPLETED",[44],"2017-08-01","2017-09-20","2015-02-01",124,[92],"Sarcopenia",[70,94],"Lactose",{"nctId":96,"briefTitle":97,"status":85,"phases":98,"primaryCompletion":99,"completion":99,"start":100,"enrollment":101,"conditions":102,"interventions":104},"NCT01951404","Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study",[44],"2016-08","2013-09",80,[103,32],"End Stage Renal Disease",[70],{"nctId":106,"briefTitle":107,"status":85,"phases":108,"primaryCompletion":109,"completion":109,"start":110,"enrollment":111,"conditions":112,"interventions":114},"NCT01147705","Allopurinol as a Possible Oxygen Sparing Agent During Exercise in Peripheral Arterial Disease",[44],"2012-07","2011-02",50,[113],"Peripheral Arterial Disease",[70],{"nctId":116,"briefTitle":117,"status":85,"phases":118,"primaryCompletion":119,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":124},"NCT00512057","APEX Study: Effects of Allopurinol on Coronary and Peripheral Endothelial Function in Patients With Cardiac Syndrome X",[44],"2010-06","2008-06",40,[123],"Syndrome X",[125],"allopurinol",{"nctId":127,"briefTitle":128,"status":85,"phases":129,"primaryCompletion":130,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":136},"NCT02237339","Does Allopurinol Reduce Thickening of the Left Ventricle of the Heart in Patient With Treated Hypertension?",[44],"2017-06","2014-09",72,[134,135],"Hypertension","Hypertrophy, Left Ventricular",[70],{"trials":138,"activeCount":51},[],{"intervention":140,"totalTrials":8,"cells":141},"Fluticasone propionate",{"EARLY_PHASE1":142,"PHASE1":144,"PHASE2":146,"PHASE3":148,"PHASE4":150,"NA":194},{"trials":143,"activeCount":51},[],{"trials":145,"activeCount":51},[],{"trials":147,"activeCount":51},[],{"trials":149,"activeCount":51},[],{"trials":151,"activeCount":51},[152,162,172,184],{"nctId":153,"briefTitle":154,"status":85,"phases":155,"primaryCompletion":156,"completion":156,"start":157,"enrollment":158,"conditions":159,"interventions":160},"NCT00995657","Dose Response of Fractional Exhaled Nitric Oxide (FeNO) to Inhaled Steroids in Mild-to-moderate Asthma",[44],"2011-12","2009-10",21,[14],[161,161],"Fluticasone Propionate",{"nctId":163,"briefTitle":164,"status":165,"phases":166,"primaryCompletion":167,"completion":167,"start":168,"enrollment":51,"conditions":169,"interventions":170},"NCT00845598","Azelastine Fluticasone Combination vs. Fluticasone","WITHDRAWN",[44],"2011-08","2010-08",[27],[171,140],"Azelastine , fluticasone",{"nctId":173,"briefTitle":174,"status":85,"phases":175,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":179,"interventions":180},"NCT00903227","Steroid Sparing Effect of Nasal Corticosteroid In Asthma And Rhinitis",[44],"2008-08","2006-12",25,[14,27],[181,182,183],"Fluticasone Evohaler pMDI","Fluticasone Evohaler","fluticasone propionate",{"nctId":185,"briefTitle":186,"status":85,"phases":187,"primaryCompletion":188,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":193},"NCT00995475","A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease",[44],"2008-11","2006-10",18,[192],"COPD",[140],{"trials":195,"activeCount":51},[],{"intervention":197,"totalTrials":198,"cells":199},"Dapagliflozin",2,{"EARLY_PHASE1":200,"PHASE1":202,"PHASE2":204,"PHASE3":206,"PHASE4":208,"NA":230},{"trials":201,"activeCount":51},[],{"trials":203,"activeCount":51},[],{"trials":205,"activeCount":51},[],{"trials":207,"activeCount":51},[],{"trials":209,"activeCount":51},[210,219],{"nctId":211,"briefTitle":212,"status":85,"phases":213,"primaryCompletion":214,"completion":214,"start":215,"enrollment":216,"conditions":217,"interventions":218},"NCT02397421","Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes",[44],"2017-08","2015-03",56,[17,29],[197],{"nctId":220,"briefTitle":221,"status":85,"phases":222,"primaryCompletion":223,"completion":224,"start":225,"enrollment":226,"conditions":227,"interventions":229},"NCT02956811","Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?",[44],"2019-03-14","2019-04-02","2017-02-14",66,[228,32],"Type 2 Diabetes",[197],{"trials":231,"activeCount":51},[],{"intervention":233,"totalTrials":198,"cells":234},"Metformin",{"EARLY_PHASE1":235,"PHASE1":237,"PHASE2":239,"PHASE3":241,"PHASE4":243,"NA":269},{"trials":236,"activeCount":51},[],{"trials":238,"activeCount":51},[],{"trials":240,"activeCount":51},[],{"trials":242,"activeCount":51},[],{"trials":244,"activeCount":51},[245,257],{"nctId":246,"briefTitle":247,"status":85,"phases":248,"primaryCompletion":249,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":255},"NCT00473876","Metformin in Insulin Resistant Left Ventricular (LV) Dysfunction (TAYSIDE Trial)",[44],"2009-04","2007-08",62,[253,254],"Congestive Heart Failure","Insulin Resistance",[233,256],"Matched Placebo",{"nctId":258,"briefTitle":259,"status":85,"phases":260,"primaryCompletion":157,"completion":157,"start":261,"enrollment":262,"conditions":263,"interventions":265},"NCT00780715","Response To Oral Agents in Diabetes (ROAD)- Pilot Study",[44],"2008-12",29,[264],"Diabetes Mellitus, Type 2",[266,267,268,233],"Gliclazide MR","Sitagliptin","Pioglitazone",{"trials":270,"activeCount":51},[],{"intervention":272,"totalTrials":198,"cells":273},"Salmeterol",{"EARLY_PHASE1":274,"PHASE1":276,"PHASE2":278,"PHASE3":280,"PHASE4":282,"NA":304},{"trials":275,"activeCount":51},[],{"trials":277,"activeCount":51},[],{"trials":279,"activeCount":51},[],{"trials":281,"activeCount":51},[],{"trials":283,"activeCount":51},[284,294],{"nctId":285,"briefTitle":286,"status":85,"phases":287,"primaryCompletion":288,"completion":288,"start":289,"enrollment":290,"conditions":291,"interventions":292},"NCT01892787","Effects of Particle Size in Small Airways Dysfunction",[44],"2014-12","2013-07",17,[14],[293,272],"Formoterol",{"nctId":295,"briefTitle":296,"status":85,"phases":297,"primaryCompletion":298,"completion":298,"start":299,"enrollment":300,"conditions":301,"interventions":302},"NCT01388595","Fluticasone and Salmeterol in Allergic Rhinitis",[44],"2010-10","2006-11",23,[27],[303,272],"FLUTICASONE PROPRIONATE",{"trials":305,"activeCount":51},[],{"intervention":307,"totalTrials":198,"cells":308},"levosalbutamol",{"EARLY_PHASE1":309,"PHASE1":311,"PHASE2":313,"PHASE3":315,"PHASE4":317,"NA":336},{"trials":310,"activeCount":51},[],{"trials":312,"activeCount":51},[],{"trials":314,"activeCount":51},[],{"trials":316,"activeCount":51},[],{"trials":318,"activeCount":51},[319,328],{"nctId":320,"briefTitle":321,"status":165,"phases":322,"primaryCompletion":323,"completion":323,"start":324,"enrollment":51,"conditions":325,"interventions":326},"NCT00830882","Peak Bronchoprotection Conferred by Levosalbutamol and Racemic Salbutamol",[44],"2010-01","2009-01",[14],[307,327],"racemic salbutamol",{"nctId":329,"briefTitle":330,"status":85,"phases":331,"primaryCompletion":332,"completion":332,"start":324,"enrollment":333,"conditions":334,"interventions":335},"NCT00831376","Trough Bronchoprotection Conferred by Levosalbutamol and Racemic Salbutamol",[44],"2012-04",30,[14],[307,327],{"trials":337,"activeCount":51},[],{"intervention":327,"totalTrials":198,"cells":339},{"EARLY_PHASE1":340,"PHASE1":342,"PHASE2":344,"PHASE3":346,"PHASE4":348,"NA":358},{"trials":341,"activeCount":51},[],{"trials":343,"activeCount":51},[],{"trials":345,"activeCount":51},[],{"trials":347,"activeCount":51},[],{"trials":349,"activeCount":51},[350,354],{"nctId":320,"briefTitle":321,"status":165,"phases":351,"primaryCompletion":323,"completion":323,"start":324,"enrollment":51,"conditions":352,"interventions":353},[44],[14],[307,327],{"nctId":329,"briefTitle":330,"status":85,"phases":355,"primaryCompletion":332,"completion":332,"start":324,"enrollment":333,"conditions":356,"interventions":357},[44],[14],[307,327],{"trials":359,"activeCount":51},[],{"intervention":361,"totalTrials":198,"cells":362},"Bisoprolol",{"EARLY_PHASE1":363,"PHASE1":365,"PHASE2":367,"PHASE3":369,"PHASE4":371,"NA":395},{"trials":364,"activeCount":51},[],{"trials":366,"activeCount":51},[],{"trials":368,"activeCount":51},[],{"trials":370,"activeCount":51},[],{"trials":372,"activeCount":51},[373,383],{"nctId":374,"briefTitle":375,"status":85,"phases":376,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":380,"interventions":381},"NCT02380053","Chronic Beta-blockade and Cardiopulmonary Exercise in COPD",[44],"2019-04-30","2016-06-07",10,[22],[361,382],"Celiprolol",{"nctId":384,"briefTitle":385,"status":85,"phases":386,"primaryCompletion":387,"completion":387,"start":388,"enrollment":190,"conditions":389,"interventions":390},"NCT01656005","Beta Blocker Therapy in Moderate to Severe COPD",[44],"2016-07","2012-08",[22],[391,361,392,393,394],"Carvedilol","Beclometasone\u002Fformoterol","Tiotropium","Beclometasone",{"trials":396,"activeCount":51},[],{"intervention":398,"totalTrials":198,"cells":399},"HFA-BDP",{"EARLY_PHASE1":400,"PHASE1":402,"PHASE2":404,"PHASE3":406,"PHASE4":408,"NA":428},{"trials":401,"activeCount":51},[],{"trials":403,"activeCount":51},[],{"trials":405,"activeCount":51},[],{"trials":407,"activeCount":51},[],{"trials":409,"activeCount":51},[410,419],{"nctId":411,"briefTitle":412,"status":85,"phases":413,"primaryCompletion":414,"completion":414,"start":415,"enrollment":416,"conditions":417,"interventions":418},"NCT00921921","Does Extra-fine Hydrofluoroalkane-beclomethasone Dipropionate (HFA-BDP) Suppress Small Airways Inflammation in Chronic Obstructive Pulmonary Disease (COPD)?",[44],"2011-10","2009-06",16,[192],[398],{"nctId":420,"briefTitle":421,"status":85,"phases":422,"primaryCompletion":423,"completion":423,"start":324,"enrollment":15,"conditions":424,"interventions":425},"NCT00829257","Additive Effects of QVAR to (Seretide) on Surrogate Markers of Airway Inflammation in Refractory Asthma",[44],"2010-07",[14],[398,426,427],"Fluticasone","Seretide",{"trials":429,"activeCount":51},[],{"intervention":426,"totalTrials":198,"cells":431},{"EARLY_PHASE1":432,"PHASE1":434,"PHASE2":436,"PHASE3":438,"PHASE4":440,"NA":456},{"trials":433,"activeCount":51},[],{"trials":435,"activeCount":51},[],{"trials":437,"activeCount":51},[],{"trials":439,"activeCount":51},[],{"trials":441,"activeCount":51},[442,446],{"nctId":420,"briefTitle":421,"status":85,"phases":443,"primaryCompletion":423,"completion":423,"start":324,"enrollment":15,"conditions":444,"interventions":445},[44],[14],[398,426,427],{"nctId":447,"briefTitle":448,"status":85,"phases":449,"primaryCompletion":450,"completion":450,"start":249,"enrollment":451,"conditions":452,"interventions":453},"NCT00830505","Fluticasone\u002FSalmeterol (FP\u002FSM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma",[44],"2010-05",38,[14],[454,455],"fluticasone\u002Fsalmeterol","fluticasone",{"trials":457,"activeCount":51},[],{"intervention":393,"totalTrials":198,"cells":459},{"EARLY_PHASE1":460,"PHASE1":462,"PHASE2":464,"PHASE3":466,"PHASE4":468,"NA":484},{"trials":461,"activeCount":51},[],{"trials":463,"activeCount":51},[],{"trials":465,"activeCount":51},[],{"trials":467,"activeCount":51},[],{"trials":469,"activeCount":51},[470,480],{"nctId":471,"briefTitle":472,"status":85,"phases":473,"primaryCompletion":474,"completion":474,"start":475,"enrollment":15,"conditions":476,"interventions":478},"NCT02039050","Evaluation of Long-Acting Muscarinic Antagonists in COPD",[44],"2015-07","2014-02",[477],"Pulmonary Disease, Chronic Obstructive",[393,479],"Aclidinium",{"nctId":384,"briefTitle":385,"status":85,"phases":481,"primaryCompletion":387,"completion":387,"start":388,"enrollment":190,"conditions":482,"interventions":483},[44],[22],[391,361,392,393,394],{"trials":485,"activeCount":51},[],{"intervention":94,"totalTrials":10,"cells":487},{"EARLY_PHASE1":488,"PHASE1":490,"PHASE2":492,"PHASE3":494,"PHASE4":496,"NA":502},{"trials":489,"activeCount":51},[],{"trials":491,"activeCount":51},[],{"trials":493,"activeCount":51},[],{"trials":495,"activeCount":51},[],{"trials":497,"activeCount":51},[498],{"nctId":83,"briefTitle":84,"status":85,"phases":499,"primaryCompletion":87,"completion":88,"start":89,"enrollment":90,"conditions":500,"interventions":501},[44],[92],[70,94],{"trials":503,"activeCount":51},[],{"intervention":505,"totalTrials":10,"cells":506},"Prednisolone",{"EARLY_PHASE1":507,"PHASE1":509,"PHASE2":511,"PHASE3":513,"PHASE4":515,"NA":527},{"trials":508,"activeCount":51},[],{"trials":510,"activeCount":51},[],{"trials":512,"activeCount":51},[],{"trials":514,"activeCount":51},[],{"trials":516,"activeCount":51},[517],{"nctId":518,"briefTitle":519,"status":85,"phases":520,"primaryCompletion":521,"completion":188,"start":522,"enrollment":523,"conditions":524,"interventions":526},"NCT00788749","Medical Polypectomy and Predictors of Response",[44],"2008-02","2004-05",60,[525],"Nasal Polyps",[505],{"trials":528,"activeCount":51},[],{"intervention":256,"totalTrials":10,"cells":530},{"EARLY_PHASE1":531,"PHASE1":533,"PHASE2":535,"PHASE3":537,"PHASE4":539,"NA":545},{"trials":532,"activeCount":51},[],{"trials":534,"activeCount":51},[],{"trials":536,"activeCount":51},[],{"trials":538,"activeCount":51},[],{"trials":540,"activeCount":51},[541],{"nctId":246,"briefTitle":247,"status":85,"phases":542,"primaryCompletion":249,"completion":249,"start":250,"enrollment":251,"conditions":543,"interventions":544},[44],[253,254],[233,256],{"trials":546,"activeCount":51},[],{"intervention":293,"totalTrials":10,"cells":548},{"EARLY_PHASE1":549,"PHASE1":551,"PHASE2":553,"PHASE3":555,"PHASE4":557,"NA":563},{"trials":550,"activeCount":51},[],{"trials":552,"activeCount":51},[],{"trials":554,"activeCount":51},[],{"trials":556,"activeCount":51},[],{"trials":558,"activeCount":51},[559],{"nctId":285,"briefTitle":286,"status":85,"phases":560,"primaryCompletion":288,"completion":288,"start":289,"enrollment":290,"conditions":561,"interventions":562},[44],[14],[293,272],{"trials":564,"activeCount":51},[],{"intervention":566,"totalTrials":10,"cells":567},"Hydrocortisone\u002F Placebo and Propranolol",{"EARLY_PHASE1":568,"PHASE1":570,"PHASE2":572,"PHASE3":574,"PHASE4":576,"NA":586},{"trials":569,"activeCount":51},[],{"trials":571,"activeCount":51},[],{"trials":573,"activeCount":51},[],{"trials":575,"activeCount":51},[],{"trials":577,"activeCount":51},[578],{"nctId":579,"briefTitle":580,"status":85,"phases":581,"primaryCompletion":168,"completion":298,"start":582,"enrollment":583,"conditions":584,"interventions":585},"NCT01070225","Reversal of Acute β-Blocker Induced Bronchoconstriction",[44],"2010-03",14,[14],[566],{"trials":587,"activeCount":51},[],{"intervention":382,"totalTrials":10,"cells":589},{"EARLY_PHASE1":590,"PHASE1":592,"PHASE2":594,"PHASE3":596,"PHASE4":598,"NA":604},{"trials":591,"activeCount":51},[],{"trials":593,"activeCount":51},[],{"trials":595,"activeCount":51},[],{"trials":597,"activeCount":51},[],{"trials":599,"activeCount":51},[600],{"nctId":374,"briefTitle":375,"status":85,"phases":601,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":602,"interventions":603},[44],[22],[361,382],{"trials":605,"activeCount":51},[],{"intervention":607,"totalTrials":10,"cells":608},"Azelastine-Fluticasone Nasal",{"EARLY_PHASE1":609,"PHASE1":611,"PHASE2":613,"PHASE3":615,"PHASE4":617,"NA":633},{"trials":610,"activeCount":51},[],{"trials":612,"activeCount":51},[],{"trials":614,"activeCount":51},[],{"trials":616,"activeCount":51},[],{"trials":618,"activeCount":51},[619],{"nctId":620,"briefTitle":621,"status":622,"phases":623,"primaryCompletion":624,"completion":624,"start":625,"enrollment":626,"conditions":627,"interventions":631},"NCT02953106","Effects of Intranasal Fluticasone Plus Azelastine on Airway Inflammation in Patients With Asthma & Allergic Rhinitis","TERMINATED",[44],"2018-09-10","2017-01-20",7,[628,629,630],"Asthma, Allergic","Rhinitis,Allergic","Allergy",[607,632],"Placebos",{"trials":634,"activeCount":51},[],{"intervention":632,"totalTrials":10,"cells":636},{"EARLY_PHASE1":637,"PHASE1":639,"PHASE2":641,"PHASE3":643,"PHASE4":645,"NA":651},{"trials":638,"activeCount":51},[],{"trials":640,"activeCount":51},[],{"trials":642,"activeCount":51},[],{"trials":644,"activeCount":51},[],{"trials":646,"activeCount":51},[647],{"nctId":620,"briefTitle":621,"status":622,"phases":648,"primaryCompletion":624,"completion":624,"start":625,"enrollment":626,"conditions":649,"interventions":650},[44],[628,629,630],[607,632],{"trials":652,"activeCount":51},[],{"intervention":654,"totalTrials":10,"cells":655},"Menthol",{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":662,"PHASE4":664,"NA":676},{"trials":657,"activeCount":51},[],{"trials":659,"activeCount":51},[],{"trials":661,"activeCount":51},[],{"trials":663,"activeCount":51},[],{"trials":665,"activeCount":51},[666],{"nctId":667,"briefTitle":668,"status":85,"phases":669,"primaryCompletion":670,"completion":670,"start":671,"enrollment":379,"conditions":672,"interventions":674},"NCT02984072","Menthol for PDT Pain Relief",[44],"2019-10-10","2018-10-23",[673],"Actinic Keratosis",[654,675],"Aqueous Cream",{"trials":677,"activeCount":51},[],{"intervention":675,"totalTrials":10,"cells":679},{"EARLY_PHASE1":680,"PHASE1":682,"PHASE2":684,"PHASE3":686,"PHASE4":688,"NA":694},{"trials":681,"activeCount":51},[],{"trials":683,"activeCount":51},[],{"trials":685,"activeCount":51},[],{"trials":687,"activeCount":51},[],{"trials":689,"activeCount":51},[690],{"nctId":667,"briefTitle":668,"status":85,"phases":691,"primaryCompletion":670,"completion":670,"start":671,"enrollment":379,"conditions":692,"interventions":693},[44],[673],[654,675],{"trials":695,"activeCount":51},[],{"intervention":171,"totalTrials":10,"cells":697},{"EARLY_PHASE1":698,"PHASE1":700,"PHASE2":702,"PHASE3":704,"PHASE4":706,"NA":712},{"trials":699,"activeCount":51},[],{"trials":701,"activeCount":51},[],{"trials":703,"activeCount":51},[],{"trials":705,"activeCount":51},[],{"trials":707,"activeCount":51},[708],{"nctId":163,"briefTitle":164,"status":165,"phases":709,"primaryCompletion":167,"completion":167,"start":168,"enrollment":51,"conditions":710,"interventions":711},[44],[27],[171,140],{"trials":713,"activeCount":51},[],{"intervention":715,"totalTrials":10,"cells":716},"Indacaterol",{"EARLY_PHASE1":717,"PHASE1":719,"PHASE2":721,"PHASE3":723,"PHASE4":725,"NA":734},{"trials":718,"activeCount":51},[],{"trials":720,"activeCount":51},[],{"trials":722,"activeCount":51},[],{"trials":724,"activeCount":51},[],{"trials":726,"activeCount":51},[727],{"nctId":728,"briefTitle":729,"status":85,"phases":730,"primaryCompletion":387,"completion":387,"start":475,"enrollment":583,"conditions":731,"interventions":732},"NCT02039011","Ultra-long Acting Bronchodilator Therapy in Asthmatics",[44],[14],[715,733],"Indacaterol and tiotropium",{"trials":735,"activeCount":51},[],{"intervention":733,"totalTrials":10,"cells":737},{"EARLY_PHASE1":738,"PHASE1":740,"PHASE2":742,"PHASE3":744,"PHASE4":746,"NA":752},{"trials":739,"activeCount":51},[],{"trials":741,"activeCount":51},[],{"trials":743,"activeCount":51},[],{"trials":745,"activeCount":51},[],{"trials":747,"activeCount":51},[748],{"nctId":728,"briefTitle":729,"status":85,"phases":749,"primaryCompletion":387,"completion":387,"start":475,"enrollment":583,"conditions":750,"interventions":751},[44],[14],[715,733],{"trials":753,"activeCount":51},[],{"intervention":755,"totalTrials":10,"cells":756},"Celecoxib",{"EARLY_PHASE1":757,"PHASE1":759,"PHASE2":761,"PHASE3":763,"PHASE4":765,"NA":779},{"trials":758,"activeCount":51},[],{"trials":760,"activeCount":51},[],{"trials":762,"activeCount":51},[],{"trials":764,"activeCount":51},[],{"trials":766,"activeCount":51},[767],{"nctId":768,"briefTitle":769,"status":85,"phases":770,"primaryCompletion":771,"completion":771,"start":772,"enrollment":773,"conditions":774,"interventions":777},"NCT00447759","The Standard Care Versus Celecoxib Outcome Trial",[44],"2015-08","2007-06",7297,[775,776],"Osteoarthritis","Rheumatoid Arthritis",[755,778],"Diclofenac",{"trials":780,"activeCount":51},[],{"intervention":778,"totalTrials":10,"cells":782},{"EARLY_PHASE1":783,"PHASE1":785,"PHASE2":787,"PHASE3":789,"PHASE4":791,"NA":797},{"trials":784,"activeCount":51},[],{"trials":786,"activeCount":51},[],{"trials":788,"activeCount":51},[],{"trials":790,"activeCount":51},[],{"trials":792,"activeCount":51},[793],{"nctId":768,"briefTitle":769,"status":85,"phases":794,"primaryCompletion":771,"completion":771,"start":772,"enrollment":773,"conditions":795,"interventions":796},[44],[775,776],[755,778],{"trials":798,"activeCount":51},[],{"intervention":800,"totalTrials":10,"cells":801},"Doxazosin XL",{"EARLY_PHASE1":802,"PHASE1":804,"PHASE2":806,"PHASE3":808,"PHASE4":810,"NA":819},{"trials":803,"activeCount":51},[],{"trials":805,"activeCount":51},[],{"trials":807,"activeCount":51},[],{"trials":809,"activeCount":51},[],{"trials":811,"activeCount":51},[812],{"nctId":813,"briefTitle":814,"status":85,"phases":815,"primaryCompletion":816,"completion":816,"start":100,"enrollment":290,"conditions":817,"interventions":818},"NCT01946035","Alpha-Blockers in Allergic Rhinitis (MAN 01)",[44],"2015-06",[27],[800],{"trials":820,"activeCount":51},[],{"intervention":822,"totalTrials":10,"cells":823},"Atorvastatin",{"EARLY_PHASE1":824,"PHASE1":826,"PHASE2":828,"PHASE3":830,"PHASE4":832,"NA":843},{"trials":825,"activeCount":51},[],{"trials":827,"activeCount":51},[],{"trials":829,"activeCount":51},[],{"trials":831,"activeCount":51},[],{"trials":833,"activeCount":51},[834],{"nctId":835,"briefTitle":836,"status":85,"phases":837,"primaryCompletion":838,"completion":838,"start":839,"enrollment":190,"conditions":840,"interventions":842},"NCT02984293","Statin Immune Study",[44],"2017-11-03","2017-04-17",[841],"Drug Intolerance",[822],{"trials":844,"activeCount":51},[],{"intervention":427,"totalTrials":10,"cells":846},{"EARLY_PHASE1":847,"PHASE1":849,"PHASE2":851,"PHASE3":853,"PHASE4":855,"NA":861},{"trials":848,"activeCount":51},[],{"trials":850,"activeCount":51},[],{"trials":852,"activeCount":51},[],{"trials":854,"activeCount":51},[],{"trials":856,"activeCount":51},[857],{"nctId":420,"briefTitle":421,"status":85,"phases":858,"primaryCompletion":423,"completion":423,"start":324,"enrollment":15,"conditions":859,"interventions":860},[44],[14],[398,426,427],{"trials":862,"activeCount":51},[],{"intervention":479,"totalTrials":10,"cells":864},{"EARLY_PHASE1":865,"PHASE1":867,"PHASE2":869,"PHASE3":871,"PHASE4":873,"NA":879},{"trials":866,"activeCount":51},[],{"trials":868,"activeCount":51},[],{"trials":870,"activeCount":51},[],{"trials":872,"activeCount":51},[],{"trials":874,"activeCount":51},[875],{"nctId":471,"briefTitle":472,"status":85,"phases":876,"primaryCompletion":474,"completion":474,"start":475,"enrollment":15,"conditions":877,"interventions":878},[44],[477],[393,479],{"trials":880,"activeCount":51},[],{"intervention":882,"totalTrials":10,"cells":883},"olodaterol hydrochloride 2.5mcg, tiotropium bromide 2.5mcg",{"EARLY_PHASE1":884,"PHASE1":886,"PHASE2":888,"PHASE3":890,"PHASE4":892,"NA":903},{"trials":885,"activeCount":51},[],{"trials":887,"activeCount":51},[],{"trials":889,"activeCount":51},[],{"trials":891,"activeCount":51},[],{"trials":893,"activeCount":51},[894],{"nctId":895,"briefTitle":896,"status":85,"phases":897,"primaryCompletion":898,"completion":898,"start":899,"enrollment":290,"conditions":900,"interventions":901},"NCT02682862","Ultra-long Acting Bronchodilator Therapy in Smoking Asthmatics",[44],"2019-05-22","2016-07-11",[14],[882,902],"olodaterol 2.5 mcg",{"trials":904,"activeCount":51},[],{"intervention":902,"totalTrials":10,"cells":906},{"EARLY_PHASE1":907,"PHASE1":909,"PHASE2":911,"PHASE3":913,"PHASE4":915,"NA":921},{"trials":908,"activeCount":51},[],{"trials":910,"activeCount":51},[],{"trials":912,"activeCount":51},[],{"trials":914,"activeCount":51},[],{"trials":916,"activeCount":51},[917],{"nctId":895,"briefTitle":896,"status":85,"phases":918,"primaryCompletion":898,"completion":898,"start":899,"enrollment":290,"conditions":919,"interventions":920},[44],[14],[882,902],{"trials":922,"activeCount":51},[],{"intervention":266,"totalTrials":10,"cells":924},{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":929,"PHASE3":931,"PHASE4":933,"NA":939},{"trials":926,"activeCount":51},[],{"trials":928,"activeCount":51},[],{"trials":930,"activeCount":51},[],{"trials":932,"activeCount":51},[],{"trials":934,"activeCount":51},[935],{"nctId":258,"briefTitle":259,"status":85,"phases":936,"primaryCompletion":157,"completion":157,"start":261,"enrollment":262,"conditions":937,"interventions":938},[44],[264],[266,267,268,233],{"trials":940,"activeCount":51},[],{"intervention":267,"totalTrials":10,"cells":942},{"EARLY_PHASE1":943,"PHASE1":945,"PHASE2":947,"PHASE3":949,"PHASE4":951,"NA":957},{"trials":944,"activeCount":51},[],{"trials":946,"activeCount":51},[],{"trials":948,"activeCount":51},[],{"trials":950,"activeCount":51},[],{"trials":952,"activeCount":51},[953],{"nctId":258,"briefTitle":259,"status":85,"phases":954,"primaryCompletion":157,"completion":157,"start":261,"enrollment":262,"conditions":955,"interventions":956},[44],[264],[266,267,268,233],{"trials":958,"activeCount":51},[],{"intervention":268,"totalTrials":10,"cells":960},{"EARLY_PHASE1":961,"PHASE1":963,"PHASE2":965,"PHASE3":967,"PHASE4":969,"NA":975},{"trials":962,"activeCount":51},[],{"trials":964,"activeCount":51},[],{"trials":966,"activeCount":51},[],{"trials":968,"activeCount":51},[],{"trials":970,"activeCount":51},[971],{"nctId":258,"briefTitle":259,"status":85,"phases":972,"primaryCompletion":157,"completion":157,"start":261,"enrollment":262,"conditions":973,"interventions":974},[44],[264],[266,267,268,233],{"trials":976,"activeCount":51},[],{"intervention":978,"totalTrials":10,"cells":979},"spironolactone",{"EARLY_PHASE1":980,"PHASE1":982,"PHASE2":984,"PHASE3":986,"PHASE4":988,"NA":1000},{"trials":981,"activeCount":51},[],{"trials":983,"activeCount":51},[],{"trials":985,"activeCount":51},[],{"trials":987,"activeCount":51},[],{"trials":989,"activeCount":51},[990],{"nctId":991,"briefTitle":992,"status":85,"phases":993,"primaryCompletion":215,"completion":994,"start":995,"enrollment":996,"conditions":997,"interventions":999},"NCT02046668","The Effect of Spironolactone on Pain in Older People With Osteoarthritis",[44],"2015-05","2013-11",86,[998],"Osteoarthritis, Knee",[978],{"trials":1001,"activeCount":51},[],{"intervention":181,"totalTrials":10,"cells":1003},{"EARLY_PHASE1":1004,"PHASE1":1006,"PHASE2":1008,"PHASE3":1010,"PHASE4":1012,"NA":1018},{"trials":1005,"activeCount":51},[],{"trials":1007,"activeCount":51},[],{"trials":1009,"activeCount":51},[],{"trials":1011,"activeCount":51},[],{"trials":1013,"activeCount":51},[1014],{"nctId":173,"briefTitle":174,"status":85,"phases":1015,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":1016,"interventions":1017},[44],[14,27],[181,182,183],{"trials":1019,"activeCount":51},[],{"intervention":182,"totalTrials":10,"cells":1021},{"EARLY_PHASE1":1022,"PHASE1":1024,"PHASE2":1026,"PHASE3":1028,"PHASE4":1030,"NA":1036},{"trials":1023,"activeCount":51},[],{"trials":1025,"activeCount":51},[],{"trials":1027,"activeCount":51},[],{"trials":1029,"activeCount":51},[],{"trials":1031,"activeCount":51},[1032],{"nctId":173,"briefTitle":174,"status":85,"phases":1033,"primaryCompletion":176,"completion":176,"start":177,"enrollment":178,"conditions":1034,"interventions":1035},[44],[14,27],[181,182,183],{"trials":1037,"activeCount":51},[],{"intervention":1039,"totalTrials":10,"cells":1040},"Empagliflozin 25mg",{"EARLY_PHASE1":1041,"PHASE1":1043,"PHASE2":1045,"PHASE3":1047,"PHASE4":1049,"NA":1062},{"trials":1042,"activeCount":51},[],{"trials":1044,"activeCount":51},[],{"trials":1046,"activeCount":51},[],{"trials":1048,"activeCount":51},[],{"trials":1050,"activeCount":51},[1051],{"nctId":1052,"briefTitle":1053,"status":85,"phases":1054,"primaryCompletion":1055,"completion":1056,"start":1057,"enrollment":300,"conditions":1058,"interventions":1060},"NCT03226457","SGLT2 Inhibition in Combination With Diuretics in Heart Failure",[44],"2018-12-11","2019-01-09","2017-12-11",[17,1059],"Type 2 Diabetes Mellitus",[1039,1061],"Frusemide",{"trials":1063,"activeCount":51},[],{"intervention":1061,"totalTrials":10,"cells":1065},{"EARLY_PHASE1":1066,"PHASE1":1068,"PHASE2":1070,"PHASE3":1072,"PHASE4":1074,"NA":1080},{"trials":1067,"activeCount":51},[],{"trials":1069,"activeCount":51},[],{"trials":1071,"activeCount":51},[],{"trials":1073,"activeCount":51},[],{"trials":1075,"activeCount":51},[1076],{"nctId":1052,"briefTitle":1053,"status":85,"phases":1077,"primaryCompletion":1055,"completion":1056,"start":1057,"enrollment":300,"conditions":1078,"interventions":1079},[44],[17,1059],[1039,1061],{"trials":1081,"activeCount":51},[],{"intervention":1083,"totalTrials":10,"cells":1084},"Qvar®",{"EARLY_PHASE1":1085,"PHASE1":1087,"PHASE2":1089,"PHASE3":1091,"PHASE4":1093,"NA":1104},{"trials":1086,"activeCount":51},[],{"trials":1088,"activeCount":51},[],{"trials":1090,"activeCount":51},[],{"trials":1092,"activeCount":51},[],{"trials":1094,"activeCount":51},[1095],{"nctId":1096,"briefTitle":1097,"status":85,"phases":1098,"primaryCompletion":1099,"completion":1099,"start":1100,"enrollment":1101,"conditions":1102,"interventions":1103},"NCT01894048","Targeted Small Airways Therapy in Persistent Asthma",[44],"2018-06-25","2013-10-28",26,[14],[1083],{"trials":1105,"activeCount":51},[],{"intervention":1107,"totalTrials":10,"cells":1108},"Tiotropium & olodaterol",{"EARLY_PHASE1":1109,"PHASE1":1111,"PHASE2":1113,"PHASE3":1115,"PHASE4":1117,"NA":1128},{"trials":1110,"activeCount":51},[],{"trials":1112,"activeCount":51},[],{"trials":1114,"activeCount":51},[],{"trials":1116,"activeCount":51},[],{"trials":1118,"activeCount":51},[1119],{"nctId":1120,"briefTitle":1121,"status":85,"phases":1122,"primaryCompletion":1123,"completion":1123,"start":1124,"enrollment":101,"conditions":1125,"interventions":1126},"NCT03152149","INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and Olodaterol",[44],"2019-11-26","2017-06-01",[22],[1107,1127],"fluticasone furoate & vilanterol",{"trials":1129,"activeCount":51},[],{"intervention":1127,"totalTrials":10,"cells":1131},{"EARLY_PHASE1":1132,"PHASE1":1134,"PHASE2":1136,"PHASE3":1138,"PHASE4":1140,"NA":1146},{"trials":1133,"activeCount":51},[],{"trials":1135,"activeCount":51},[],{"trials":1137,"activeCount":51},[],{"trials":1139,"activeCount":51},[],{"trials":1141,"activeCount":51},[1142],{"nctId":1120,"briefTitle":1121,"status":85,"phases":1143,"primaryCompletion":1123,"completion":1123,"start":1124,"enrollment":101,"conditions":1144,"interventions":1145},[44],[22],[1107,1127],{"trials":1147,"activeCount":51},[],{"intervention":1149,"totalTrials":10,"cells":1150},"Diazoxide",{"EARLY_PHASE1":1151,"PHASE1":1153,"PHASE2":1155,"PHASE3":1157,"PHASE4":1159,"NA":1170},{"trials":1152,"activeCount":51},[],{"trials":1154,"activeCount":51},[],{"trials":1156,"activeCount":51},[],{"trials":1158,"activeCount":51},[],{"trials":1160,"activeCount":51},[1161],{"nctId":1162,"briefTitle":1163,"status":85,"phases":1164,"primaryCompletion":1165,"completion":1165,"start":1166,"enrollment":1167,"conditions":1168,"interventions":1169},"NCT01488136","Use of Diazoxide in Acute Hypoglycaemia",[44],"2013-03","2012-01",12,[25],[1149],{"trials":1171,"activeCount":51},[],{"intervention":1173,"totalTrials":10,"cells":1174},"Alpha 1-Proteinase Inhibitor 180mg\u002Fkg",{"EARLY_PHASE1":1175,"PHASE1":1177,"PHASE2":1179,"PHASE3":1181,"PHASE4":1183,"NA":1197},{"trials":1176,"activeCount":51},[],{"trials":1178,"activeCount":51},[],{"trials":1180,"activeCount":51},[],{"trials":1182,"activeCount":51},[],{"trials":1184,"activeCount":51},[1185],{"nctId":1186,"briefTitle":1187,"status":85,"phases":1188,"primaryCompletion":1189,"completion":1189,"start":1190,"enrollment":1191,"conditions":1192,"interventions":1194},"NCT05582798","Bronchiectasis Alpha-1 Augmentation Trial- Modulating Airway Neutrophil Function",[44],"2024-08-12","2022-11-01",20,[1193],"Bronchiectasis Adult",[1173,1195,1196],"Alpha 1-Proteinase Inhibitor 120mg\u002Fkg","Sodium chloride",{"trials":1198,"activeCount":51},[],{"intervention":1195,"totalTrials":10,"cells":1200},{"EARLY_PHASE1":1201,"PHASE1":1203,"PHASE2":1205,"PHASE3":1207,"PHASE4":1209,"NA":1215},{"trials":1202,"activeCount":51},[],{"trials":1204,"activeCount":51},[],{"trials":1206,"activeCount":51},[],{"trials":1208,"activeCount":51},[],{"trials":1210,"activeCount":51},[1211],{"nctId":1186,"briefTitle":1187,"status":85,"phases":1212,"primaryCompletion":1189,"completion":1189,"start":1190,"enrollment":1191,"conditions":1213,"interventions":1214},[44],[1193],[1173,1195,1196],{"trials":1216,"activeCount":51},[],{"intervention":1196,"totalTrials":10,"cells":1218},{"EARLY_PHASE1":1219,"PHASE1":1221,"PHASE2":1223,"PHASE3":1225,"PHASE4":1227,"NA":1233},{"trials":1220,"activeCount":51},[],{"trials":1222,"activeCount":51},[],{"trials":1224,"activeCount":51},[],{"trials":1226,"activeCount":51},[],{"trials":1228,"activeCount":51},[1229],{"nctId":1186,"briefTitle":1187,"status":85,"phases":1230,"primaryCompletion":1189,"completion":1189,"start":1190,"enrollment":1191,"conditions":1231,"interventions":1232},[44],[1193],[1173,1195,1196],{"trials":1234,"activeCount":51},[],{"intervention":1236,"totalTrials":10,"cells":1237},"Budesonide & formoterol fumarate and Aclidinium bromide",{"EARLY_PHASE1":1238,"PHASE1":1240,"PHASE2":1242,"PHASE3":1244,"PHASE4":1246,"NA":1260},{"trials":1239,"activeCount":51},[],{"trials":1241,"activeCount":51},[],{"trials":1243,"activeCount":51},[],{"trials":1245,"activeCount":51},[],{"trials":1247,"activeCount":51},[1248],{"nctId":1249,"briefTitle":1250,"status":85,"phases":1251,"primaryCompletion":1252,"completion":1252,"start":1253,"enrollment":1254,"conditions":1255,"interventions":1256},"NCT02972476","Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial",[44],"2019-07-22","2016-12",158,[22],[1236,1257,1258,1259],"Fluticasone 500 & salmeterol and Aclidinium bromide","Fluticasone 250 & salmeterol and Aclidinium bromide","Aclidinium bromide & formoterol fumarate",{"trials":1261,"activeCount":51},[],{"intervention":1257,"totalTrials":10,"cells":1263},{"EARLY_PHASE1":1264,"PHASE1":1266,"PHASE2":1268,"PHASE3":1270,"PHASE4":1272,"NA":1278},{"trials":1265,"activeCount":51},[],{"trials":1267,"activeCount":51},[],{"trials":1269,"activeCount":51},[],{"trials":1271,"activeCount":51},[],{"trials":1273,"activeCount":51},[1274],{"nctId":1249,"briefTitle":1250,"status":85,"phases":1275,"primaryCompletion":1252,"completion":1252,"start":1253,"enrollment":1254,"conditions":1276,"interventions":1277},[44],[22],[1236,1257,1258,1259],{"trials":1279,"activeCount":51},[],{"intervention":1258,"totalTrials":10,"cells":1281},{"EARLY_PHASE1":1282,"PHASE1":1284,"PHASE2":1286,"PHASE3":1288,"PHASE4":1290,"NA":1296},{"trials":1283,"activeCount":51},[],{"trials":1285,"activeCount":51},[],{"trials":1287,"activeCount":51},[],{"trials":1289,"activeCount":51},[],{"trials":1291,"activeCount":51},[1292],{"nctId":1249,"briefTitle":1250,"status":85,"phases":1293,"primaryCompletion":1252,"completion":1252,"start":1253,"enrollment":1254,"conditions":1294,"interventions":1295},[44],[22],[1236,1257,1258,1259],{"trials":1297,"activeCount":51},[],{"intervention":1259,"totalTrials":10,"cells":1299},{"EARLY_PHASE1":1300,"PHASE1":1302,"PHASE2":1304,"PHASE3":1306,"PHASE4":1308,"NA":1314},{"trials":1301,"activeCount":51},[],{"trials":1303,"activeCount":51},[],{"trials":1305,"activeCount":51},[],{"trials":1307,"activeCount":51},[],{"trials":1309,"activeCount":51},[1310],{"nctId":1249,"briefTitle":1250,"status":85,"phases":1311,"primaryCompletion":1252,"completion":1252,"start":1253,"enrollment":1254,"conditions":1312,"interventions":1313},[44],[22],[1236,1257,1258,1259],{"trials":1315,"activeCount":51},[],{"intervention":1317,"totalTrials":10,"cells":1318},"Metformin XL",{"EARLY_PHASE1":1319,"PHASE1":1321,"PHASE2":1323,"PHASE3":1325,"PHASE4":1327,"NA":1340},{"trials":1320,"activeCount":51},[],{"trials":1322,"activeCount":51},[],{"trials":1324,"activeCount":51},[],{"trials":1326,"activeCount":51},[],{"trials":1328,"activeCount":51},[1329],{"nctId":1330,"briefTitle":1331,"status":85,"phases":1332,"primaryCompletion":1333,"completion":1334,"start":215,"enrollment":1335,"conditions":1336,"interventions":1339},"NCT02226510","MetfoRmin and Its Effects on Left Ventricular Hypertrophy in Normotensive Patients With Coronary Artery Disease",[44],"2017-09","2017-12",68,[32,254,1337,1338],"Coronary Artery Disease","PreDiabetes",[1317],{"trials":1341,"activeCount":51},[],{"intervention":303,"totalTrials":10,"cells":1343},{"EARLY_PHASE1":1344,"PHASE1":1346,"PHASE2":1348,"PHASE3":1350,"PHASE4":1352,"NA":1358},{"trials":1345,"activeCount":51},[],{"trials":1347,"activeCount":51},[],{"trials":1349,"activeCount":51},[],{"trials":1351,"activeCount":51},[],{"trials":1353,"activeCount":51},[1354],{"nctId":295,"briefTitle":296,"status":85,"phases":1355,"primaryCompletion":298,"completion":298,"start":299,"enrollment":300,"conditions":1356,"interventions":1357},[44],[27],[303,272],{"trials":1359,"activeCount":51},[],{"intervention":391,"totalTrials":10,"cells":1361},{"EARLY_PHASE1":1362,"PHASE1":1364,"PHASE2":1366,"PHASE3":1368,"PHASE4":1370,"NA":1376},{"trials":1363,"activeCount":51},[],{"trials":1365,"activeCount":51},[],{"trials":1367,"activeCount":51},[],{"trials":1369,"activeCount":51},[],{"trials":1371,"activeCount":51},[1372],{"nctId":384,"briefTitle":385,"status":85,"phases":1373,"primaryCompletion":387,"completion":387,"start":388,"enrollment":190,"conditions":1374,"interventions":1375},[44],[22],[391,361,392,393,394],{"trials":1377,"activeCount":51},[],{"intervention":392,"totalTrials":10,"cells":1379},{"EARLY_PHASE1":1380,"PHASE1":1382,"PHASE2":1384,"PHASE3":1386,"PHASE4":1388,"NA":1394},{"trials":1381,"activeCount":51},[],{"trials":1383,"activeCount":51},[],{"trials":1385,"activeCount":51},[],{"trials":1387,"activeCount":51},[],{"trials":1389,"activeCount":51},[1390],{"nctId":384,"briefTitle":385,"status":85,"phases":1391,"primaryCompletion":387,"completion":387,"start":388,"enrollment":190,"conditions":1392,"interventions":1393},[44],[22],[391,361,392,393,394],{"trials":1395,"activeCount":51},[],{"intervention":394,"totalTrials":10,"cells":1397},{"EARLY_PHASE1":1398,"PHASE1":1400,"PHASE2":1402,"PHASE3":1404,"PHASE4":1406,"NA":1412},{"trials":1399,"activeCount":51},[],{"trials":1401,"activeCount":51},[],{"trials":1403,"activeCount":51},[],{"trials":1405,"activeCount":51},[],{"trials":1407,"activeCount":51},[1408],{"nctId":384,"briefTitle":385,"status":85,"phases":1409,"primaryCompletion":387,"completion":387,"start":388,"enrollment":190,"conditions":1410,"interventions":1411},[44],[22],[391,361,392,393,394],{"trials":1413,"activeCount":51},[],{"intervention":1415,"totalTrials":10,"cells":1416},"Aztreonam lysine",{"EARLY_PHASE1":1417,"PHASE1":1419,"PHASE2":1421,"PHASE3":1423,"PHASE4":1425,"NA":1437},{"trials":1418,"activeCount":51},[],{"trials":1420,"activeCount":51},[],{"trials":1422,"activeCount":51},[],{"trials":1424,"activeCount":51},[],{"trials":1426,"activeCount":51},[1427],{"nctId":1428,"briefTitle":1429,"status":622,"phases":1430,"primaryCompletion":1431,"completion":1432,"start":1433,"enrollment":1434,"conditions":1435,"interventions":1436},"NCT03696290","Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis",[44],"2024-11-26","2025-03-04","2019-10-19",34,[1193],[1415],{"trials":1438,"activeCount":51},[],{"intervention":454,"totalTrials":10,"cells":1440},{"EARLY_PHASE1":1441,"PHASE1":1443,"PHASE2":1445,"PHASE3":1447,"PHASE4":1449,"NA":1455},{"trials":1442,"activeCount":51},[],{"trials":1444,"activeCount":51},[],{"trials":1446,"activeCount":51},[],{"trials":1448,"activeCount":51},[],{"trials":1450,"activeCount":51},[1451],{"nctId":447,"briefTitle":448,"status":85,"phases":1452,"primaryCompletion":450,"completion":450,"start":249,"enrollment":451,"conditions":1453,"interventions":1454},[44],[14],[454,455],{"trials":1456,"activeCount":51},[],{"intervention":1458,"totalTrials":10,"cells":1459},"Active Comparator: Vigantol Oil",{"EARLY_PHASE1":1460,"PHASE1":1462,"PHASE2":1464,"PHASE3":1466,"PHASE4":1477,"NA":1479},{"trials":1461,"activeCount":51},[],{"trials":1463,"activeCount":51},[],{"trials":1465,"activeCount":51},[],{"trials":1467,"activeCount":51},[1468],{"nctId":1469,"briefTitle":1470,"status":85,"phases":1471,"primaryCompletion":1472,"completion":1473,"start":475,"enrollment":132,"conditions":1474,"interventions":1475},"NCT02053519","Can Vitamin D Supplementation Improve Hepatitis C Cure Rates",[43],"2016-04","2016-10",[20],[1458,1476],"Mygliol Oil",{"trials":1478,"activeCount":51},[],{"trials":1480,"activeCount":51},[],{"intervention":1476,"totalTrials":10,"cells":1482},{"EARLY_PHASE1":1483,"PHASE1":1485,"PHASE2":1487,"PHASE3":1489,"PHASE4":1495,"NA":1497},{"trials":1484,"activeCount":51},[],{"trials":1486,"activeCount":51},[],{"trials":1488,"activeCount":51},[],{"trials":1490,"activeCount":51},[1491],{"nctId":1469,"briefTitle":1470,"status":85,"phases":1492,"primaryCompletion":1472,"completion":1473,"start":475,"enrollment":132,"conditions":1493,"interventions":1494},[43],[20],[1458,1476],{"trials":1496,"activeCount":51},[],{"trials":1498,"activeCount":51},[],{"intervention":1500,"totalTrials":10,"cells":1501},"rosuvastatin",{"EARLY_PHASE1":1502,"PHASE1":1504,"PHASE2":1506,"PHASE3":1508,"PHASE4":1518,"NA":1520},{"trials":1503,"activeCount":51},[],{"trials":1505,"activeCount":51},[],{"trials":1507,"activeCount":51},[],{"trials":1509,"activeCount":51},[1510],{"nctId":1511,"briefTitle":1512,"status":85,"phases":1513,"primaryCompletion":1514,"completion":1514,"start":1515,"enrollment":111,"conditions":1516,"interventions":1517},"NCT00679510","Rosuvastatin in Rheumatoid Arthritis (RORA)",[42,43],"2008-01","2004-02",[776],[1500],{"trials":1519,"activeCount":51},[],{"trials":1521,"activeCount":51},[],{"intervention":1523,"totalTrials":10,"cells":1524},"Saxagliptin",{"EARLY_PHASE1":1525,"PHASE1":1527,"PHASE2":1529,"PHASE3":1531,"PHASE4":1543,"NA":1545},{"trials":1526,"activeCount":51},[],{"trials":1528,"activeCount":51},[],{"trials":1530,"activeCount":51},[],{"trials":1532,"activeCount":51},[1533],{"nctId":1534,"briefTitle":1535,"status":85,"phases":1536,"primaryCompletion":1537,"completion":1537,"start":1538,"enrollment":1539,"conditions":1540,"interventions":1542},"NCT01922817","DPP4inhibitors in Type 1 Diabetes",[43],"2014-04","2012-09",28,[25,1541],"Hypoglycaemia",[1523],{"trials":1544,"activeCount":51},[],{"trials":1546,"activeCount":51},[],{"intervention":1548,"totalTrials":10,"cells":1549},"Brensocatib",{"EARLY_PHASE1":1550,"PHASE1":1552,"PHASE2":1554,"PHASE3":1556,"PHASE4":1568,"NA":1570},{"trials":1551,"activeCount":51},[],{"trials":1553,"activeCount":51},[],{"trials":1555,"activeCount":51},[],{"trials":1557,"activeCount":51},[1558],{"nctId":1559,"briefTitle":1560,"status":85,"phases":1561,"primaryCompletion":1562,"completion":1562,"start":1563,"enrollment":1564,"conditions":1565,"interventions":1567},"NCT04817332","STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19",[43],"2021-02-28","2020-06-05",406,[1566],"Covid19",[1548],{"trials":1569,"activeCount":51},[],{"trials":1571,"activeCount":51},[],{"intervention":1573,"totalTrials":198,"cells":1574},"propranolol",{"EARLY_PHASE1":1575,"PHASE1":1577,"PHASE2":1579,"PHASE3":1599,"PHASE4":1601,"NA":1603},{"trials":1576,"activeCount":51},[],{"trials":1578,"activeCount":51},[],{"trials":1580,"activeCount":51},[1581,1588],{"nctId":1582,"briefTitle":1583,"status":85,"phases":1584,"primaryCompletion":1585,"completion":1585,"start":450,"enrollment":190,"conditions":1586,"interventions":1587},"NCT01074853","Beta Blockers for the Treatment of Asthma",[42],"2012-03",[14],[1573],{"nctId":1589,"briefTitle":1590,"status":85,"phases":1591,"primaryCompletion":1592,"completion":1592,"start":1593,"enrollment":416,"conditions":1594,"interventions":1595},"NCT01544634","Beta Blocker Therapy in Mild to Moderate Asthmatics",[42],"2013-05-25","2012-04-04",[14],[1596,1597,1598],"Propranolol","Qvar 50","Qvar 100",{"trials":1600,"activeCount":51},[],{"trials":1602,"activeCount":51},[],{"trials":1604,"activeCount":51},[],{"intervention":1606,"totalTrials":10,"cells":1607},"Elbasvir\u002FGrazoprevir 50 MG-100 MG Oral",{"EARLY_PHASE1":1608,"PHASE1":1610,"PHASE2":1612,"PHASE3":1625,"PHASE4":1627,"NA":1629},{"trials":1609,"activeCount":51},[],{"trials":1611,"activeCount":51},[],{"trials":1613,"activeCount":51},[1614],{"nctId":1615,"briefTitle":1616,"status":85,"phases":1617,"primaryCompletion":1618,"completion":1619,"start":1620,"enrollment":1621,"conditions":1622,"interventions":1623},"NCT03236506","A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study",[42],"2020-08-31","2020-10-28","2018-01-19",129,[20],[1606,1624],"Sofosbuvir 400 MG",{"trials":1626,"activeCount":51},[],{"trials":1628,"activeCount":51},[],{"trials":1630,"activeCount":51},[],{"intervention":1624,"totalTrials":10,"cells":1632},{"EARLY_PHASE1":1633,"PHASE1":1635,"PHASE2":1637,"PHASE3":1643,"PHASE4":1645,"NA":1647},{"trials":1634,"activeCount":51},[],{"trials":1636,"activeCount":51},[],{"trials":1638,"activeCount":51},[1639],{"nctId":1615,"briefTitle":1616,"status":85,"phases":1640,"primaryCompletion":1618,"completion":1619,"start":1620,"enrollment":1621,"conditions":1641,"interventions":1642},[42],[20],[1606,1624],{"trials":1644,"activeCount":51},[],{"trials":1646,"activeCount":51},[],{"trials":1648,"activeCount":51},[],{"intervention":1597,"totalTrials":10,"cells":1650},{"EARLY_PHASE1":1651,"PHASE1":1653,"PHASE2":1655,"PHASE3":1661,"PHASE4":1663,"NA":1665},{"trials":1652,"activeCount":51},[],{"trials":1654,"activeCount":51},[],{"trials":1656,"activeCount":51},[1657],{"nctId":1589,"briefTitle":1590,"status":85,"phases":1658,"primaryCompletion":1592,"completion":1592,"start":1593,"enrollment":416,"conditions":1659,"interventions":1660},[42],[14],[1596,1597,1598],{"trials":1662,"activeCount":51},[],{"trials":1664,"activeCount":51},[],{"trials":1666,"activeCount":51},[],{"intervention":1598,"totalTrials":10,"cells":1668},{"EARLY_PHASE1":1669,"PHASE1":1671,"PHASE2":1673,"PHASE3":1679,"PHASE4":1681,"NA":1683},{"trials":1670,"activeCount":51},[],{"trials":1672,"activeCount":51},[],{"trials":1674,"activeCount":51},[1675],{"nctId":1589,"briefTitle":1590,"status":85,"phases":1676,"primaryCompletion":1592,"completion":1592,"start":1593,"enrollment":416,"conditions":1677,"interventions":1678},[42],[14],[1596,1597,1598],{"trials":1680,"activeCount":51},[],{"trials":1682,"activeCount":51},[],{"trials":1684,"activeCount":51},[],{"intervention":1686,"totalTrials":10,"cells":1687},"Tadalafil",{"EARLY_PHASE1":1688,"PHASE1":1690,"PHASE2":1692,"PHASE3":1703,"PHASE4":1705,"NA":1707},{"trials":1689,"activeCount":51},[],{"trials":1691,"activeCount":51},[],{"trials":1693,"activeCount":51},[1694],{"nctId":1695,"briefTitle":1696,"status":85,"phases":1697,"primaryCompletion":1538,"completion":1538,"start":1698,"enrollment":1699,"conditions":1700,"interventions":1702},"NCT01197469","Do Phosphodiesterase 5A Inhibitors Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Hypertension?",[42],"2010-09",120,[22,1701],"Pulmonary Hypertension",[1686],{"trials":1704,"activeCount":51},[],{"trials":1706,"activeCount":51},[],{"trials":1708,"activeCount":51},[],{"intervention":1710,"totalTrials":10,"cells":1711},"Cefuroxime",{"EARLY_PHASE1":1712,"PHASE1":1714,"PHASE2":1716,"PHASE3":1718,"PHASE4":1720,"NA":1722},{"trials":1713,"activeCount":51},[],{"trials":1715,"activeCount":51},[],{"trials":1717,"activeCount":51},[],{"trials":1719,"activeCount":51},[],{"trials":1721,"activeCount":51},[],{"trials":1723,"activeCount":51},[1724],{"nctId":1725,"briefTitle":1726,"status":85,"phases":1727,"primaryCompletion":261,"completion":261,"start":1728,"enrollment":121,"conditions":1729,"interventions":1731},"NCT00355602","Antibiotics for the Treatment of Ulcerative Colitis",[45],"2006-07",[1730],"Colitis, Ulcerative",[1710,1732,1733,1734,1735,1736,1737,1738,1739,1740],"Ciprofloxacin","Clarithromycin","Cotrimoxazole","Coamoxiclav","metronidazole","neomycin","rifaximin","Vancomycin","Doxycycline",{"intervention":1732,"totalTrials":10,"cells":1742},{"EARLY_PHASE1":1743,"PHASE1":1745,"PHASE2":1747,"PHASE3":1749,"PHASE4":1751,"NA":1753},{"trials":1744,"activeCount":51},[],{"trials":1746,"activeCount":51},[],{"trials":1748,"activeCount":51},[],{"trials":1750,"activeCount":51},[],{"trials":1752,"activeCount":51},[],{"trials":1754,"activeCount":51},[1755],{"nctId":1725,"briefTitle":1726,"status":85,"phases":1756,"primaryCompletion":261,"completion":261,"start":1728,"enrollment":121,"conditions":1757,"interventions":1758},[45],[1730],[1710,1732,1733,1734,1735,1736,1737,1738,1739,1740],{"intervention":1733,"totalTrials":10,"cells":1760},{"EARLY_PHASE1":1761,"PHASE1":1763,"PHASE2":1765,"PHASE3":1767,"PHASE4":1769,"NA":1771},{"trials":1762,"activeCount":51},[],{"trials":1764,"activeCount":51},[],{"trials":1766,"activeCount":51},[],{"trials":1768,"activeCount":51},[],{"trials":1770,"activeCount":51},[],{"trials":1772,"activeCount":51},[1773],{"nctId":1725,"briefTitle":1726,"status":85,"phases":1774,"primaryCompletion":261,"completion":261,"start":1728,"enrollment":121,"conditions":1775,"interventions":1776},[45],[1730],[1710,1732,1733,1734,1735,1736,1737,1738,1739,1740],{"intervention":1734,"totalTrials":10,"cells":1778},{"EARLY_PHASE1":1779,"PHASE1":1781,"PHASE2":1783,"PHASE3":1785,"PHASE4":1787,"NA":1789},{"trials":1780,"activeCount":51},[],{"trials":1782,"activeCount":51},[],{"trials":1784,"activeCount":51},[],{"trials":1786,"activeCount":51},[],{"trials":1788,"activeCount":51},[],{"trials":1790,"activeCount":51},[1791],{"nctId":1725,"briefTitle":1726,"status":85,"phases":1792,"primaryCompletion":261,"completion":261,"start":1728,"enrollment":121,"conditions":1793,"interventions":1794},[45],[1730],[1710,1732,1733,1734,1735,1736,1737,1738,1739,1740],{"intervention":1735,"totalTrials":10,"cells":1796},{"EARLY_PHASE1":1797,"PHASE1":1799,"PHASE2":1801,"PHASE3":1803,"PHASE4":1805,"NA":1807},{"trials":1798,"activeCount":51},[],{"trials":1800,"activeCount":51},[],{"trials":1802,"activeCount":51},[],{"trials":1804,"activeCount":51},[],{"trials":1806,"activeCount":51},[],{"trials":1808,"activeCount":51},[1809],{"nctId":1725,"briefTitle":1726,"status":85,"phases":1810,"primaryCompletion":261,"completion":261,"start":1728,"enrollment":121,"conditions":1811,"interventions":1812},[45],[1730],[1710,1732,1733,1734,1735,1736,1737,1738,1739,1740],{"intervention":1736,"totalTrials":10,"cells":1814},{"EARLY_PHASE1":1815,"PHASE1":1817,"PHASE2":1819,"PHASE3":1821,"PHASE4":1823,"NA":1825},{"trials":1816,"activeCount":51},[],{"trials":1818,"activeCount":51},[],{"trials":1820,"activeCount":51},[],{"trials":1822,"activeCount":51},[],{"trials":1824,"activeCount":51},[],{"trials":1826,"activeCount":51},[1827],{"nctId":1725,"briefTitle":1726,"status":85,"phases":1828,"primaryCompletion":261,"completion":261,"start":1728,"enrollment":121,"conditions":1829,"interventions":1830},[45],[1730],[1710,1732,1733,1734,1735,1736,1737,1738,1739,1740],{"intervention":1737,"totalTrials":10,"cells":1832},{"EARLY_PHASE1":1833,"PHASE1":1835,"PHASE2":1837,"PHASE3":1839,"PHASE4":1841,"NA":1843},{"trials":1834,"activeCount":51},[],{"trials":1836,"activeCount":51},[],{"trials":1838,"activeCount":51},[],{"trials":1840,"activeCount":51},[],{"trials":1842,"activeCount":51},[],{"trials":1844,"activeCount":51},[1845],{"nctId":1725,"briefTitle":1726,"status":85,"phases":1846,"primaryCompletion":261,"completion":261,"start":1728,"enrollment":121,"conditions":1847,"interventions":1848},[45],[1730],[1710,1732,1733,1734,1735,1736,1737,1738,1739,1740],{"intervention":1738,"totalTrials":10,"cells":1850},{"EARLY_PHASE1":1851,"PHASE1":1853,"PHASE2":1855,"PHASE3":1857,"PHASE4":1859,"NA":1861},{"trials":1852,"activeCount":51},[],{"trials":1854,"activeCount":51},[],{"trials":1856,"activeCount":51},[],{"trials":1858,"activeCount":51},[],{"trials":1860,"activeCount":51},[],{"trials":1862,"activeCount":51},[1863],{"nctId":1725,"briefTitle":1726,"status":85,"phases":1864,"primaryCompletion":261,"completion":261,"start":1728,"enrollment":121,"conditions":1865,"interventions":1866},[45],[1730],[1710,1732,1733,1734,1735,1736,1737,1738,1739,1740],{"intervention":1739,"totalTrials":10,"cells":1868},{"EARLY_PHASE1":1869,"PHASE1":1871,"PHASE2":1873,"PHASE3":1875,"PHASE4":1877,"NA":1879},{"trials":1870,"activeCount":51},[],{"trials":1872,"activeCount":51},[],{"trials":1874,"activeCount":51},[],{"trials":1876,"activeCount":51},[],{"trials":1878,"activeCount":51},[],{"trials":1880,"activeCount":51},[1881],{"nctId":1725,"briefTitle":1726,"status":85,"phases":1882,"primaryCompletion":261,"completion":261,"start":1728,"enrollment":121,"conditions":1883,"interventions":1884},[45],[1730],[1710,1732,1733,1734,1735,1736,1737,1738,1739,1740],{"intervention":1740,"totalTrials":10,"cells":1886},{"EARLY_PHASE1":1887,"PHASE1":1889,"PHASE2":1891,"PHASE3":1893,"PHASE4":1895,"NA":1897},{"trials":1888,"activeCount":51},[],{"trials":1890,"activeCount":51},[],{"trials":1892,"activeCount":51},[],{"trials":1894,"activeCount":51},[],{"trials":1896,"activeCount":51},[],{"trials":1898,"activeCount":51},[1899],{"nctId":1725,"briefTitle":1726,"status":85,"phases":1900,"primaryCompletion":261,"completion":261,"start":1728,"enrollment":121,"conditions":1901,"interventions":1902},[45],[1730],[1710,1732,1733,1734,1735,1736,1737,1738,1739,1740],{"intervention":1904,"totalTrials":10,"cells":1905},"Gliclazide",{"EARLY_PHASE1":1906,"PHASE1":1908,"PHASE2":1910,"PHASE3":1912,"PHASE4":1914,"NA":1916},{"trials":1907,"activeCount":51},[],{"trials":1909,"activeCount":51},[],{"trials":1911,"activeCount":51},[],{"trials":1913,"activeCount":51},[],{"trials":1915,"activeCount":51},[],{"trials":1917,"activeCount":51},[1918],{"nctId":1919,"briefTitle":1920,"status":85,"phases":1921,"primaryCompletion":1922,"completion":1922,"start":1923,"enrollment":1191,"conditions":1924,"interventions":1925},"NCT03705195","Study of Sulphonylurea Synergy With Incretins",[45],"2019-06-26","2018-08-03",[1059],[1904],{"intervention":1927,"totalTrials":10,"cells":1928},"Montelukast Placebo",{"EARLY_PHASE1":1929,"PHASE1":1931,"PHASE2":1933,"PHASE3":1935,"PHASE4":1937,"NA":1939},{"trials":1930,"activeCount":51},[],{"trials":1932,"activeCount":51},[],{"trials":1934,"activeCount":51},[],{"trials":1936,"activeCount":51},[],{"trials":1938,"activeCount":51},[],{"trials":1940,"activeCount":51},[1941],{"nctId":1942,"briefTitle":1943,"status":85,"phases":1944,"primaryCompletion":1945,"completion":1946,"start":250,"enrollment":1947,"conditions":1948,"interventions":1949},"NCT00655616","Add-on Salmeterol Versus Montelukast in Arg\u002FArg-16 Asthmatics",[45],"2009-08","2009-12",64,[14],[1927,1950],"Salmeterol, Montelukast",{"intervention":1950,"totalTrials":10,"cells":1952},{"EARLY_PHASE1":1953,"PHASE1":1955,"PHASE2":1957,"PHASE3":1959,"PHASE4":1961,"NA":1963},{"trials":1954,"activeCount":51},[],{"trials":1956,"activeCount":51},[],{"trials":1958,"activeCount":51},[],{"trials":1960,"activeCount":51},[],{"trials":1962,"activeCount":51},[],{"trials":1964,"activeCount":51},[1965],{"nctId":1942,"briefTitle":1943,"status":85,"phases":1966,"primaryCompletion":1945,"completion":1946,"start":250,"enrollment":1947,"conditions":1967,"interventions":1968},[45],[14],[1927,1950],{"intervention":1970,"totalTrials":10,"cells":1971},"Exenatide, Liraglutide",{"EARLY_PHASE1":1972,"PHASE1":1974,"PHASE2":1976,"PHASE3":1978,"PHASE4":1980,"NA":1982},{"trials":1973,"activeCount":51},[],{"trials":1975,"activeCount":51},[],{"trials":1977,"activeCount":51},[],{"trials":1979,"activeCount":51},[],{"trials":1981,"activeCount":51},[],{"trials":1983,"activeCount":51},[1984],{"nctId":1985,"briefTitle":1986,"status":85,"phases":1987,"primaryCompletion":474,"completion":1988,"start":1989,"enrollment":1990,"conditions":1991,"interventions":1992},"NCT01575301","DIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R Agonists",[45],"2015-12-11","2011-03",411,[29],[1970],{"intervention":1994,"totalTrials":10,"cells":1995},"Identification of genetic causes of diabetic neuropathic pain",{"EARLY_PHASE1":1996,"PHASE1":1998,"PHASE2":2000,"PHASE3":2002,"PHASE4":2004,"NA":2006},{"trials":1997,"activeCount":51},[],{"trials":1999,"activeCount":51},[],{"trials":2001,"activeCount":51},[],{"trials":2003,"activeCount":51},[],{"trials":2005,"activeCount":51},[],{"trials":2007,"activeCount":51},[2008],{"nctId":2009,"briefTitle":2010,"status":85,"phases":2011,"primaryCompletion":2012,"completion":2012,"start":2013,"enrollment":2014,"conditions":2015,"interventions":2017},"NCT02783469","Genetics of Diabetes Audit and Research in Tayside Scotland (DOLORisk Dundee)",[],"2009-05-31","2004-10",1915,[2016],"Diabetic Neuropathic Pain",[1994],{"intervention":2019,"totalTrials":10,"cells":2020},"Sulfonylurea",{"EARLY_PHASE1":2021,"PHASE1":2023,"PHASE2":2025,"PHASE3":2027,"PHASE4":2029,"NA":2031},{"trials":2022,"activeCount":51},[],{"trials":2024,"activeCount":51},[],{"trials":2026,"activeCount":51},[],{"trials":2028,"activeCount":51},[],{"trials":2030,"activeCount":51},[],{"trials":2032,"activeCount":51},[2033],{"nctId":2034,"briefTitle":2035,"status":85,"phases":2036,"primaryCompletion":2037,"completion":2037,"start":2038,"enrollment":333,"conditions":2039,"interventions":2040},"NCT04192292","Study of Sulphonylurea Synergy With DPP4 Inhibitors",[45],"2020-12-02","2019-10-08",[228],[2019,2041],"DPP4 Inhibitor",{"intervention":2041,"totalTrials":10,"cells":2043},{"EARLY_PHASE1":2044,"PHASE1":2046,"PHASE2":2048,"PHASE3":2050,"PHASE4":2052,"NA":2054},{"trials":2045,"activeCount":51},[],{"trials":2047,"activeCount":51},[],{"trials":2049,"activeCount":51},[],{"trials":2051,"activeCount":51},[],{"trials":2053,"activeCount":51},[],{"trials":2055,"activeCount":51},[2056],{"nctId":2034,"briefTitle":2035,"status":85,"phases":2057,"primaryCompletion":2037,"completion":2037,"start":2038,"enrollment":333,"conditions":2058,"interventions":2059},[45],[228],[2019,2041],{"intervention":2061,"totalTrials":10,"cells":2062},"Synbiotic",{"EARLY_PHASE1":2063,"PHASE1":2065,"PHASE2":2067,"PHASE3":2069,"PHASE4":2071,"NA":2073},{"trials":2064,"activeCount":51},[],{"trials":2066,"activeCount":51},[],{"trials":2068,"activeCount":51},[],{"trials":2070,"activeCount":51},[],{"trials":2072,"activeCount":51},[],{"trials":2074,"activeCount":51},[2075],{"nctId":2076,"briefTitle":2077,"status":85,"phases":2078,"primaryCompletion":261,"completion":261,"start":2079,"enrollment":111,"conditions":2080,"interventions":2082},"NCT00305409","Synbiotic Treatment in Crohn's Disease Patients",[45],"2006-06",[2081],"Crohn's Disease",[2061],{"intervention":2084,"totalTrials":10,"cells":2085},"Lithium Carbonate",{"EARLY_PHASE1":2086,"PHASE1":2088,"PHASE2":2090,"PHASE3":2092,"PHASE4":2094,"NA":2096},{"trials":2087,"activeCount":51},[],{"trials":2089,"activeCount":51},[],{"trials":2091,"activeCount":51},[],{"trials":2093,"activeCount":51},[],{"trials":2095,"activeCount":51},[],{"trials":2097,"activeCount":51},[2098],{"nctId":2099,"briefTitle":2100,"status":85,"phases":2101,"primaryCompletion":130,"completion":130,"start":99,"enrollment":2102,"conditions":2103,"interventions":2105},"NCT02601859","Evaluation of Lithium as a Glycogen-Synthase-Kinase-3 (GSK-3) Inhibitor in Mild Cognitive Impairment",[45],11,[2104],"Mild Cognitive Impairment",[2084]]